 This study investigates the use of spectral event analysis to identify potential biomarkers of effective repetitive, transcranial magnetic stimulation, RTMS, treatments for major depressive disorder, MDD, and post-traumatic stress disorder, PTSD. The study found that certain spectral event features, such as frontal beta event frequency spans and durations, and central beta event maxima power, were associated with improvements in both MDD and PTSD symptoms following RTMS treatment. These findings suggest that spectral event analysis could be used to identify individuals who would benefit most from RTMS treatments. This article was authored by Alexander T. Morris, Simona Temmerianca, Amin Sandvikili, and others.